These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
738 related articles for article (PubMed ID: 21115743)
1. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Li H; Cai Q; Godwin AK; Zhang R Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743 [TBL] [Abstract][Full Text] [Related]
2. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK. Li H; Cai Q; Wu H; Vathipadiekal V; Dobbin ZC; Li T; Hua X; Landen CN; Birrer MJ; Sánchez-Beato M; Zhang R Mol Cancer Res; 2012 Nov; 10(11):1462-72. PubMed ID: 22964433 [TBL] [Abstract][Full Text] [Related]
3. NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells. Garipov A; Li H; Bitler BG; Thapa RJ; Balachandran S; Zhang R Mol Cancer Res; 2013 Apr; 11(4):360-9. PubMed ID: 23360797 [TBL] [Abstract][Full Text] [Related]
4. EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer. Fu Y; Chen J; Pang B; Li C; Zhao J; Shen K Cell Biochem Biophys; 2015 Jan; 71(1):105-12. PubMed ID: 25077680 [TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412 [TBL] [Abstract][Full Text] [Related]
6. ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Li H; Bitler BG; Vathipadiekal V; Maradeo ME; Slifker M; Creasy CL; Tummino PJ; Cairns P; Birrer MJ; Zhang R Cancer Prev Res (Phila); 2012 Mar; 5(3):484-91. PubMed ID: 22144423 [TBL] [Abstract][Full Text] [Related]
8. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893 [TBL] [Abstract][Full Text] [Related]
9. Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Kemp CD; Rao M; Xi S; Inchauste S; Mani H; Fetsch P; Filie A; Zhang M; Hong JA; Walker RL; Zhu YJ; Ripley RT; Mathur A; Liu F; Yang M; Meltzer PA; Marquez VE; De Rienzo A; Bueno R; Schrump DS Clin Cancer Res; 2012 Jan; 18(1):77-90. PubMed ID: 22028491 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362 [TBL] [Abstract][Full Text] [Related]
11. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma. Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081 [TBL] [Abstract][Full Text] [Related]
12. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Amatangelo MD; Garipov A; Li H; Conejo-Garcia JR; Speicher DW; Zhang R Cell Cycle; 2013 Jul; 12(13):2113-9. PubMed ID: 23759589 [TBL] [Abstract][Full Text] [Related]
13. The role of EZH2 and DNA methylation in hMLH1 silencing in epithelial ovarian cancer. Wang J; Yu L; Cai J; Jia J; Gao Y; Liang M; Wang Z Biochem Biophys Res Commun; 2013 Apr; 433(4):470-6. PubMed ID: 23523787 [TBL] [Abstract][Full Text] [Related]
14. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008 [TBL] [Abstract][Full Text] [Related]
15. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Wei Y; Chen YH; Li LY; Lang J; Yeh SP; Shi B; Yang CC; Yang JY; Lin CY; Lai CC; Hung MC Nat Cell Biol; 2011 Jan; 13(1):87-94. PubMed ID: 21131960 [TBL] [Abstract][Full Text] [Related]
16. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826 [TBL] [Abstract][Full Text] [Related]
17. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648 [TBL] [Abstract][Full Text] [Related]
18. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837 [TBL] [Abstract][Full Text] [Related]
19. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis. Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863 [TBL] [Abstract][Full Text] [Related]
20. EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1. Li T; Cai J; Ding H; Xu L; Yang Q; Wang Z Cancer Biol Ther; 2014 Mar; 15(3):271-8. PubMed ID: 24335192 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]